RP Bio Inc.

314140 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

5,000.00KRW-130.00 (-2.53%)

Price History

Full chart

Market Stats

Previous Close5,130.00

Open5,120.00

Day Range4,980.00 – 5,190.00

52-Week Range4,810.00 – 9,067.81

Volume24.97K

Market Cap51.38B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.84%

Beta0.41

50-Day Avg6,009.00

200-Day Avg6,220.35

About

RP Bio Inc., a bio-health company, engages in the research, development, manufacture, and sale of soft capsules in Korea and internationally. It offers animal, vegetable, antihistamine, and chewable soft capsules; hard capsules; and jelly and powder sticks; Urusa, flagship soft capsule; omega-3 and lutein products, and granule, effervescent granule, and stick type capsule powders. The company also provides cold and liver medicines; vitamins; blood circulation improvers; and pain relievers. The company was founded in 1983 and is headquartered in Seoul, South Korea.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOJae-Hoon Yoon
Headquarters8th floor, Samseong-dong, Seoul, South Korea, Korea
Websitehttps://www.rpbio.co.kr

Leadership

Jae-Hoon YoonCEO & Inside Director · b. 1961
Hyun-sun KimCEO, President & Inside Director · b. 1972

Financials

Income Statement

Currency: KRW	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	138.11B	151.05B	123.97B	136.22B
Growth (%)	-	+9.37%	-17.93%	+9.88%
Cost of Revenue	120.33B	135.48B	116.77B	122.38B
Gross Profit	17.78B	15.57B	7.20B	13.84B
Gross Margin	12.87%	10.31%	5.81%	10.16%
Operating Expense	8.13B	8.95B	7.89B	8.75B
Operating Income	9.65B	6.62B	-693.64M	5.09B
Operating Margin	6.98%	4.38%	-0.56%	3.73%
EBITDA	12.26B	13.50B	6.85B	11.87B
EBITDA Margin	8.87%	8.94%	5.53%	8.72%
Net Income	4.32B	5.44B	-907.12M	4.68B
Net Income Margin	3.12%	3.60%	-0.73%	3.44%
Interest Expense	1.18B	1.80B	1.25B	829.23M
Interest Expense % of Total Revenue	0.86%	1.19%	1.01%	0.61%

Balance Sheet

Currency: KRW	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	173.16B	166.22B	159.50B	156.26B
Total Liabilities	82.02B	63.47B	57.20B	49.06B
Total Equity	91.14B	102.75B	102.30B	107.20B
Cash	16.82B	3.21B	14.13B	9.85B
Net Debt	18.06B	21.79B	10.87B	6.15B

Cash Flow

Currency: KRW	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	1.15B	10.58B	13.52B	12.48B
Capital Expenditure	5.28B	11.16B	6.01B	5.61B
Free Cash Flow	-4.12B	-584.33M	7.51B	6.86B
Dividends Paid	-	-	432.49M	-
FCF to OCF	-357.07%	-5.52%	55.55%	55.02%
Dividend Paid to FCF	-	-	5.76%	-

Earnings

Report Date	Sep 30, 2022	Dec 31, 2022	Mar 31, 2023	Jun 30, 2023	Sep 30, 2023	Dec 31, 2023	Mar 31, 2024	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024	Mar 31, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	204.37	-414.81	63.60	243.01	375.81	-53.83	-59.89	13.79	-182.41	123.64	196.09	213.54	31.94	99.75	302.50	343.38
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap51.38B

Enterprise Value50.95B

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.36

Price / Book0.44

Revenue (TTM)141.42B

Gross Profit (TTM)16.43B

EBITDA13.55B

Profit Margin4.76%

Operating Margin10.29%

Return on Equity6.07%

Return on Assets2.84%

Shares Outstanding8.65M

Shares Float3.30M

Beta0.41

Dividend Yield0.84%

Dividend Rate50.00

Payout Ratio6.43%

Dividends

20251×

50.00Dec 29, 2025

20231×

50.00Dec 27, 2023